Cartesian Therapeutics, Inc. revenue
Cartesian Therapeutics, Inc.'s revenue was $2.8m in fiscal 2025, down 92.8% on the year before. Since fiscal 2014 ($3.0m) it has grown at a compound -0.8% a year. Over the last twelve months it was $1.5m.
Revenue history
| Fiscal year | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 6 | 8 | 0 | 1 | 7 | 17 | 85 | 111 | 26 | 39 | 3 | 1 |
| Growth on the year before | — | +97.7% | +34.5% | −97.4% | +336.2% | +639.4% | +148.6% | +412.6% | +30.2% | −76.5% | +49.6% | −92.8% | — |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Cartesian Therapeutics, Inc. | $1.5m | 44.0% | -68.8% |
| Absci Corp | $1.6m | -62.3% | -43.3% |
| Ovid Therapeutics Inc. | $1.6m | -76.2% | 99.8% |
| Dare Bioscience, Inc. | $1.4m | 4366.5% | — |
| Longeveron Inc. | $1.2m | -42.7% | 10.4% |
| Seres Therapeutics, Inc. | $1.9m | 100.0% | -75.6% |
Compare with peers
- Absci Corp revenue
- Ovid Therapeutics Inc. revenue
- Dare Bioscience, Inc. revenue
- Longeveron Inc. revenue
- Seres Therapeutics, Inc. revenue
Head to head: ABSI vs RNACOVID vs RNACDARE vs RNACLGVN vs RNAC
More: Biotechnology stocks compared, Health Care sector, rankings of US companies